Lantern Pharma reports extended survival in lung cancer trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Lantern Pharma reports extended survival in lung cancer trial
(NASDAQ: LTRN) Delayed: 3.88 +0.09 (2.37%)
Previous Close $3.79    52 Week High $ 
Open $3.84    52 Week Low $ 
Day High $4.10    P/E N/A 
Day Low $3.77    EPS $ 
Volume 104,334